Catabasis Pharmaceuticals snaps up HAE antibody in buyout; Gladstone, UCSF scientist spearhead launch of neuro research center
A few months after finally admitting defeat on their failed Duchenne MD program, Catabasis Pharmaceuticals is heading in a new direction with the purchase of Quellis Biosciences and their lead antibody for hereditary angioedema.
Catabasis shared the news on Friday that they’re buying out Quellis, a rare disease-focused biotech that was unveiled over a year ago by Chris Garabedian and Perceptive Advisors’ PXV Fund. With it, Catabasis is snapping up QLS-215, a monoclonal antibody inhibitor of plasma kallikrein. The candidate is currently in preclinical development — but won’t be for long, according to Catabasis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.